Based on the ALEX study of ALK+ NSCLC with brain metastasis, alectinib showed a higher ALK inhibitory potency,40 BBB transport, superior CNS activity, and significantly delayed CNS progression, irrespective of prior CNS disease or radiotherapy when compared to CRZ.41, 42, 43, 44. Here, ALK is linked to non-small cell lung carcinoma.